Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Milan
Clinical trial register · Italy

Clinical Trials in Milan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 50 Naples 37 Roma 24 Pisa 17 Florence 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
IRCCS San Raffaele160 AstraZeneca138 Merck Sharp & Dohme LLC98 Hoffmann-La Roche81 Novartis Pharmaceuticals73 Clear sponsor filter
Site location
Milan50 Naples37 Roma24 Pisa17 Florence17
All 69 locations
Target enrolment
to

Trials with a site in Milan

50 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Bristol-Myers Squibb
Phase 3
850
Meldola, Candiolo, Bergamo, Brescia, Milan, Pavia, Verona
2026-09-30
Recruiting
Bristol-Myers Squibb
Phase 2
160
Misterbianco, Bari, Bergamo, Milan, Ravenna, Rozzano (MI)
2026-09-10
Recruiting
Bristol-Myers Squibb
Phase 2
260
Siena, Bergamo, Milan, Naples, Perugia
2026-07-27
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Verona, Milan, Napoli Campania
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
Meldola, Pisa, Milan
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Naples, Ravenna, Aviano, Orbassano, Rome, Milan, Parma
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Naples, Turin, Padova, Milan, Roma
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Ferrara (Cona), Aviano, Catania, Candiolo, Genova, Milan, Naples, Novara
2026-03-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Naples, Ravenna, Aviano, Orbassano, Siena, Perugia, Bologna, Milan
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Castellana Grotte, San Giovanni Rotondo, Tricase, Milan, Aviano, Pisa, Padova, Avellino
2025-12-31
Recruiting
Bristol-Myers Squibb
Phase 3
650
Naples, Rome, Milan, Pisa, Brescia, Isernia, Roma
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Ravenna, Aviano, Orbassano, Candiolo, Avellino, Milan, Naples, Parma
2025-11-05
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Meldola, Rome, Milan, Rozzano, Pisa, Padova, Naples, Verona
2025-10-23
Recruiting
Bristol-Myers Squibb
Phase 3
424
Milan, Pisa, Siena, Ancona, Genova
2025-10-08
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Bari, Genoa, Rome, Pisa, Castelfranco Veneto, Milan, Naples, Parma
2025-09-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Naples, Bologna, Aviano, Genoa, Pontedera, Prato, Milan, Novara
2025-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
182
Naples, Monza, Milan, Padova, Bologna
2025-09-09
Recruiting
Bristol-Myers Squibb
Phase 3
450
Milan, Pisa, Siena, Ancona, Genova
2025-07-18
Recruiting
Bristol-Myers Squibb
Phase 3
426
Naples, Rome, Milan, Pisa, Brescia, Isernia, Roma
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
586
Milan, Monza, Brescia
2025-07-14
Recruiting
Bristol-Myers Squibb
Phase 3
274
Milan, Pisa, Siena, Ancona, Genova
2025-06-13
Recruiting
Bristol-Myers Squibb
Phase 3
194
Naples, Milan, Rome
2025-04-08
Recruiting
Bristol-Myers Squibb
Phase 3
530
Naples, Milan, Rome, Perugia, Peschiera del Garda, Bologna
2025-02-25
Recruiting
Bristol-Myers Squibb
Phase 1/2
413
Milan, Rozzano
2025-02-17
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
Aviano, Milan, Candiolo, Florence, Roma
2025-02-04
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Bari, Ravenna, Monza, Milan, Naples, Rome, Peschiera del Garda, Bergamo
2024-10-07
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 1
240
Milan
2024-09-06
Recruiting
Bristol-Myers Squibb
Phase 1/2
224
Milan, Padua, Verona
2024-07-17
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Bologna, Brescia, Milan, Pisa, Ravenna, Roma, Verona
2023-12-29
Active, closed
Bristol-Myers Squibb
Phase 3
190
Aviano, Milan, Monza, Naples, Rome
2023-12-21
Active, closed
Bristol-Myers Squibb
Phase 2
100
Bergamo, Meldola, Milan, Padova, Roma, Torino, Naples
2023-11-06
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Ancona, Modena, Florence, Milan, Pisa, Roma, Trieste, Bergamo
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
402
Rome, Milan, Rozzano, Turin, Florence, Bologna, Reggio Calabria, Roma
2023-10-24
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Bologna, Modena, Florence, Milan, Pisa, Roma, Ancona, Bergamo
2023-09-14
Active, closed
Bristol-Myers Squibb
Phase 3
774
Brescia, Milan, Naples, Pisa, Rome, Udine
2023-09-11
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Catania, Florence, Genova, Milan, Pisa, Roma, Torino, Naples
2023-06-22
Active, closed
Bristol-Myers Squibb
Phase 3
579
Genova, Siena, Bari, Milan, Naples, Perugia, Roma
2023-03-06
Active, closed
Bristol-Myers Squibb
Phase 3
516
Rome, Milan, Pisa, Padova, Brescia, Naples, Verona
2023-01-12
Active, closed
Bristol-Myers Squibb
Phase 3
606
Meldola, Milan, Rozzano, Bologna, Catanzaro, Lecce, Pisa, Udine
2023-01-10
Recruiting
Bristol-Myers Squibb
Phase 3
102
Genoa, Milan, Torino
2021-07-21
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 1/2
1,109
Rozzano, Candiolo, Milan, Naples, Roma, Siena
2021-05-27
Active, closed
Bristol-Myers Squibb
Phase 3
681
Cremona, Florence, Meldola, Milan, Padova, Parma, Pavia, Roma
2021-05-21
Active, closed
Bristol-Myers Squibb
Phase 3
461
Forlì, Milan, Parma
2019-11-05
Active, closed
Bristol-Myers Squibb
Phase 3
790
Palermo, Bergamo, Milan, Naples, Padova, Perugia, Siena
2019-10-28
Active, closed
Bristol-Myers Squibb
Phase 3
839
Catania, Genova, Milan, Naples, Padova, Roma
2019-08-05
Active, closed
Bristol-Myers Squibb
Phase 3
437
Brescia, Arezzo, Aviano (PN), Milan, Parma, Roma
2019-06-21
Active, closed
Bristol-Myers Squibb
Phase 3
545
Messina, Bologna, Florence, Meldola, Milan, Modena, Monserrato, Naples
2018-04-18
Active, closed
Bristol-Myers Squibb
Phase 2/3
714
Turin, Bergamo, Milan, Naples, Padova, Siena
2018-04-11
Active, closed
Bristol-Myers Squibb
Phase 3
1,314
Arezzo, Faenza, Forlì, Grosseto, Milan, Naples
2017-03-24
Active, closed
Bristol-Myers Squibb
Observational
2,555
Pesaro, Ancona, Cagliari, Florence, Lecce, Messina, Milan, Naples
2012-06-13
Rows per page Showing 1–50 of 50
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/milan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 50 of those studies with a site in Milan that also match the filters currently applied.

How many clinical trials are recruiting in Milan?

29 of the 50 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Milan), 50 studies
PhaseStudiesRecruitingShare
Phase 3291258%
Phase 2/38616%
Phase 1/27714%
Phase 2438%
Observational102%
Phase 1112%

Most active sponsors

Lead sponsors with the most studies (Milan)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb5029
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.